Abstract PO-63: A phase 2a open-label study of MT-3724, a novel CD20-targeting engineered toxin body, in combination with lenalidomide (LEN) in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL)

2020 ◽  
Author(s):  
Jason Tache ◽  
Deborah A. Katz ◽  
Amitabha Mazumder ◽  
David Peace ◽  
Christine Burnett ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Non Hodgkin Lymphoma

Phase 2, open-label study of CUDC-907 with and without rituximab in patients with relapsed/refractory MYC-altered diffuse large B-cell lymphoma.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS7579-TPS7579
Author(s):  
Daniel Jeffrey Landsburg ◽  
Kevin Kelly ◽  
Jaye Viner ◽  
Jing Wang ◽  
Lucy Gong ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

The Lancet ◽  
2021 ◽  
Author(s):  
Martin Hutchings ◽  
Rogier Mous ◽  
Michael Roost Clausen ◽  
Peter Johnson ◽  
Kim M Linton ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Dose Escalation ◽  
Phase 1 ◽  
Open Label ◽  
Non Hodgkin Lymphoma ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document